SimplicityDx Respiratory Panel submission (2025)
Molecular Designs filed a 510(k) for a panel detecting SARS-CoV-2 with two targets, influenza A, influenza B and RSV with two targets, plus an internal control. The company promoted a breakaway format to cut waste and manage inventory.
The November 2026 clearance covers influenza A, influenza B and RSV. The announcement does not say what happened to the SARS-CoV-2 configuration.
The company's first cleared diagnostic arrived with a narrower menu than the one it originally described.
The clearance is a step in a product sequence, not a standalone event, and the gap between filing and clearance defines what the company can sell now.
